Wegovy is approved for use in people with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related medical condition
This pattern of weight regain reflects the underlying pathophysiology of obesity as a chronic disease characterized by biological adaptations that defend against weight loss
Part of the PlexusDx Education Hub evidence-based GLP-1, metabolic, and genetics education
However, the remaining two-thirds had readings between 5.7% and 6.5%, in the prediabetes range
Watsons approach focuses on starting with a low dose to let your body adapt naturally while maintaining comfort and safety
Shima Hadidchi MD Family Practice, we are committed to helping our patients achieve and maintain a healthy weight through comprehensive, evidence-based care